American Journal of Medical Sciences and Medicine
ISSN (Print): 2327-6681 ISSN (Online): 2327-6657 Website: http://www.sciepub.com/journal/ajmsm Editor-in-chief: Apply for this position
Open Access
Journal Browser
Go
American Journal of Medical Sciences and Medicine. 2016, 4(4), 77-81
DOI: 10.12691/ajmsm-4-4-2
Open AccessArticle

Low Paraoxonase 1 Activity in Diabetes Mellitus as Predictors of Proliferative Diabetic Retinopathy and Macular Edema

Narin NASIROGLU IMGA1, , Hilal BITEN2, Zeliha YAZAR3, 4, Mehmet ONEN3, Canan TOPCUOGLU5, Serhat HAYME6, Dilek BERKER1 and Serdar GULER1, 7

1Ankara Numune Education and Research Hospital Department of Endocrinology, Ankara, Turkey

2Bursa Mustafakemalpasa Hospital, Bursa, Turkey

3Ankara Numune Education and Research Hospital Department of Ophthalmology, Ankara, Turkey

4Kafkas University Faculty of Medicine Department of Ophthalmology, Kars, Turkey

5Ankara Numune Education and Research Hospital Department of Clinical Biochemistry, Ankara, Turkey

6Ankara University School of Medicine Department of Biostatistics, Ankara, Turkey

7Hitit University Faculty of Medicine Department of Endocrinology, Corum, Turkey

Pub. Date: October 09, 2016

Cite this paper:
Narin NASIROGLU IMGA, Hilal BITEN, Zeliha YAZAR, Mehmet ONEN, Canan TOPCUOGLU, Serhat HAYME, Dilek BERKER and Serdar GULER. Low Paraoxonase 1 Activity in Diabetes Mellitus as Predictors of Proliferative Diabetic Retinopathy and Macular Edema. American Journal of Medical Sciences and Medicine. 2016; 4(4):77-81. doi: 10.12691/ajmsm-4-4-2

Abstract

Purpose: Diabetic retinopathy (DR) is a frequent complication of DM (Diabetes Mellitus) and a leading cause of visual impairments. Serum paraoxonase 1 (PON1) is an antioxidant enzyme that has antiatherogenic properties and plays a role in inhibiting the oxidation of low-density lipoprotein (LDL). We investigate the levels of serum PON1 activity and low-grade inflammatory markers in patients with proliferative DR (PDR) or nonproliferative DR (NPDR); and with or without diabetic macular edema (DME). Methods: We evaluated 91 DM patients and 40 controls. Serum PON1 activity, HbA1c, lipid profile, hsCRP, homocysteine (Hcy), neutrophil to lymphocyte ratio (NLR) levels were compared between patients without DR, with DR and control groups. Patients with DR were evaluated according to PDR or NPDR and the presence of macular edema or not. Results: Patients with DR and without DR, the HbA1c, LDL, NLR, Hcy, hsCRP levels were found significantly higher than controls, while serum PON1 activity was not differ. Serum PON1 activity was found significantly lower in patients with PDR and DME. Conclusion: We found serum PON1 activity was significantly lower in PDR and DME patients. Low PON1 activity may be a risk factor for PDR and DME and can be useful for further evaluation.

Keywords:
Paraoxonase 1 Proliferative Retinopathy Macular Edema Diabetes Mellitus

Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]  Ciulla TA, Amador AG and Zinman B. Diabetic retinopathy and diabetic macular edema pathophysiology, screening, and novel therapies. Diabetes care 2003, 26 (9): 2653-2664.
 
[2]  Kirpichnikov D and Sowers JR. Diabetes mellitus and diabetes-associated vascular disease. Trends Endocrinol Metab 2001, 12(5): 225-230.
 
[3]  Lyons TJ, Li W, Wells-Knecht MC and Jokl R. Toxicity of mildly modified low-density lipoproteins to cultured retinal capillary endothelial cells and pericytes. Diabetes 1994, 43(9): 1090-1095.
 
[4]  Sorenson RC, Primo-Parmo SL, Kuo CL, Adkins S, Lockridge O and La Du BN. Reconsideration of the catalytic center and mechanism of mammalian paraoxonase/arylesterase. Proc Natl Acad Sci USA. 1995, 92(16): 7187-7191.
 
[5]  Durrington PN, Mackness B and Mackness MI. Paraoxonase and atherosclerosis. Arterioscler Thromb Vasc Biol 2001, 21(4): 473-480.
 
[6]  Mackness B, Durrington PN, Boulton AJ, Hine D and Mackness MI. Serum paraoxonase activity in patients with type 1 diabetes compared to healthy controls. Eur J Clin Invest 2002, 32(4): 259-264.
 
[7]  Hultberg B, Agardh E, Andersson A, Brattström L, Isaksson A, Israelsson B and Agardh CD. Increased levels of plasma homocysteine are associated with nephropathy, but not severe retinopathy in type 1 diabetes mellitus. Scand J Clin Lab Invest 1991, 51(3): 277-282.
 
[8]  Perła-Kaján J and Jakubowski H. Paraoxonase 1 and homocysteine metabolism. Amino Acids 2012, 43(4): 1405-1417.
 
[9]  Anderson JL, Muhlestein JB, Horne BD, Carlquist JF, Bair TL, Madsen TE and Pearson RR. Plasma homocysteine predicts mortality independently of traditional risk factors and C-reactive protein in patients with angiographically defined coronary artery disease. Circulation 2000, 102(11): 1227-1232.
 
[10]  Ghorbanihaghjo A, Javadzadeh A, Argani H, Nezami N, Rashtchizadeh N, Rafeey M, Rohbaninoubar M and Rahimi-Ardabili B. Lipoprotein (a), homocysteine, and retinal arteriosclerosis. 2008.
 
[11]  Javadzadeh A, Ghorbanihaghjo A, Bahreini E, Rashtchizadeh N, Argani H and Alizadeh S. Serum paraoxonase phenotype distribution in exudative age-related macular degeneration and its relationship to homocysteine and oxidized low-density lipoprotein. Retina 2012, 32(4): 658-666.
 
[12]  Tamhane UU, Aneja S, Montgomery D, Rogers EK, Eagle KA and Gurm HS. Association between admission neutrophil to lymphocyte ratio and outcomes in patients with acute coronary syndrome. Am J Cardiol 2008, 102(6): 653-657.
 
[13]  Wang RT, Zhang JR, Li Y, Liu T and Yu KJ. Neutrophil–Lymphocyte ratio is associated with arterial stiffness in diabetic retinopathy in type 2 diabetes. J Diabetes Complications 2015, 29(8): 245-249.
 
[14]  Kang ES, Kim HJ, Ahn CW, Park CW, Cha BS, Lim SK, Kim KR and Lee HC. Relationship of serum high sensitivity C-reactive protein to metabolic syndrome and microvascular complications in type 2 diabetes. Diabetes Res Clin Pract 2005, 69(2): 151-159.
 
[15]  Mackness B, Hine D, McElduff P and Mackness M. High C-reactive protein and low paraoxonase1 in diabetes as risk factors for coronary heart disease. Atherosclerosis 2006, 186(2): 396-401.
 
[16]  American Diabetes Association. “2. Classification and diagnosis of diabetes.” Diabetes Care 38.Supplement 1 2015, S8-S16.dz.
 
[17]  Evans JL, Goldfine ID, Maddux BA and Grodsky GM. Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes. Endocr Rev 2002, 23(5): 599-622.
 
[18]  Giugliano D, Ceriello and Paolisso G. Oxidative stress and diabetic vascular complications. Diabetes care 1996, 19(3): 257-267.
 
[19]  Kaur C, Foulds WS, Ling EA. Blood–retinal barrier in hypoxic ischaemic conditions: basic concepts, clinical features and management. Prog Retin Eye Res 2008, 27(6): 622-647.
 
[20]  Aiello LP, Cahill MT and Wong JS. Systemic considerations in the management of diabetic retinopathy. Am J Ophthalmol 2001, 132(5): 760-776.
 
[21]  Mackness B, Durrington PN, Abuashia B, Boulton AJ and Mackness MI. Low paraoxonase activity in type II diabetes mellitus complicated by retinopathy. Clin Sci 2000, 98(3): 355-363.
 
[22]  Budak YU, Akdogan M and Huysal K. Relationship of PON1 activity and hsCRP concentration with disease status in patients with type 2 diabetes mellitus with and without retinopathy. Int J Diabetes Dev Ctries 2013, 33(1): 40-45.
 
[23]  Raptis AE and G Viberti. “Pathogenesis of diabetic nephropathy.” Experimental and clinical endocrinology & diabetes: official journal, German Society of Endocrinology [and] German Diabetes Association 2001, 109(Suppl 2): 424-437.
 
[24]  Elman MJ, Aiello LP, Beck RW, Bressler NM, Bressler SB, Edwards AR, Ferris FL, Friedman SM, Glassman AR, Miller KM and Scott IU. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2010, 117(6): 1064-1077.
 
[25]  Ferretti G, Bacchetti T, Busni D, Rabini RA and Curatola G. Protective effect of paraoxonase activity in high-density lipoproteins against erythrocyte membranes peroxidation: A comparison between healthy subjects and type 1 diabetic patients. J Clin Endocrinol Metab 2004, 89(6): 2957-2962.
 
[26]  Feingold KR, Memon RA, Moser AH and Grunfeld C. Paraoxonase activity in the serum and hepatic mRNA levels decrease during the acute phase response. Atherosclerosis 1998, 139(2): 307-315.
 
[27]  Barathi S, Angayarkanni N, Pasupathi A, Natarajan SK, Pukraj R, Dhupper M, Velpandian T, Muralidharan C and Sivashanmugham M. Homocysteinethiolactone and Paraoxonase Novel markers of diabetic retinopathy. Diabetes care 2010, 33(9): 2031-2037.
 
[28]  Kern TS. Contributions of inflammatory processes to the development of the early stages of diabetic retinopathy. J Diabetes Res 2007 Sep 30, 2007.
 
[29]  Van Hecke MV, Dekker JM, Nijpels G, Moll AC, Heine RJ, Bouter LM, Polak BC and Stehouwer CD. Inflammation and endothelial dysfunction are associated with retinopathy: the Hoorn Study. Diabetologia 2005, 48(7): 1300-1306.
 
[30]  Boyer DS, Faber D, Gupta S, Patel SS, Tabandeh H, Li XY, Liu CC, Lou J, Whitcup SM and Ozurdex CHAMPLAIN Study Group. Dexamethasone intravitreal implant for treatment of diabetic macular edema in vitrectomized patients. Retina 2011, 31(5): 915-923.
 
[31]  Ulu SM, Dogan M, Ahsen A, Altug A, Demir K, Acartürk G and Inan S. Neutrophil-to-lymphocyte ratio as a quick and reliable predictive marker to diagnose the severity of diabetic retinopathy. Diabetes Technol Ther 2013, 15(11): 942-947.
 
[32]  Deakin SP and James RW. Genetic and environmental factors modulating serum concentrations and activities of the antioxidant enzyme paraoxonase-1. Clin Sci 2004, 107(5): 435-447.
 
[33]  Deakin S, Leviev I, Guernier S and James RW. Simvastatin Modulates Expression of the PON1 Gene and Increases Serum Paraoxonase A Role for Sterol Regulatory Element–Binding Protein-2. Arterioscler Thromb Vasc Biol 2003, 23(11): 2083-2089.
 
[34]  Mackness B and Mackness M. Anti-inflammatory properties of paraoxonase-1 in atherosclerosis. In Paraoxonases in Inflammation, Infection, and Toxicology 2010 (pp. 143-151). Humana Press.